No Data
Baiyunshan ph (600332.SH): Its subsidiary obtained the supplementary application approval for chemical raw materials active pharmaceutical ingredient.
On October 15, Gelonghui reported that Baiyunshan Pharmaceuticals (600332.SH) announced that its subsidiary, Baiyunshan Pharmaceutical Group Co., Ltd., Baiyunshan Chemical Pharmaceuticals Factory (referred to as "Baiyunshan Chemical Pharmaceuticals Factory"), received the "Chemical Raw Materials Supplementary Application Approval Notice" issued by the National Medical Products Administration. Cefuroxime Sodium is used for the following infections caused by sensitive bacteria: respiratory tract infections, otolaryngology infections, urinary tract infections, skin and soft tissue infections, sepsis, meningitis, gonorrhea, bone and joint infections, etc.
baiyunshan (00874.HK) received approval from the National Pharmaceutical Regulatory Agency for the issuance of the 'Drug Registration Certificate' for Tadalafil Tablets (10mg).
Gelonghui October 14 | Pharmaceutical company baiyunshan (00874.HK) announced that recently, the Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") subsidiary Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical Factory (hereinafter referred to as "Baiyunshan Pharmaceutical Factory") received the "Pharmaceutical Registration Certificate" approved and issued by the National Medical Products Administration for Tadalafil tablets (10mg). Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor, mainly used to treat male erectile dysfunction (ED). It was originally researched by Eli Lilly and Company, approved in November 2002 and January 2003 respectively.
Baiyunshan (00874.HK) held a board of directors meeting on October 25 to review and approve the performance of the first three quarters.
Galaxy Today, October 14th, baiyunshan (00874.HK) announced that it will hold a board of directors meeting on October 25, 2024 (Friday) to review and approve the unaudited financial performance of the company and its subsidiaries for the nine months ended September 30, 2024, and deal with other matters (if any).
BAIYUNSHAN PH: DATE OF BOARD MEETING
Baiyunshan (600332.SH): Subsidiary pharmaceutical products pass generic drug consistency evaluation.
On October 11, Gelonghui reported that Baiyunshan (600332.SH) announced that its holding subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (referred to as "Tianxin Pharmaceutical"), has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. The injection cephalosporin sodium (0.5g, 1.0g) has passed the generic drug quality and efficacy consistency evaluation. Cefuroxime sodium is a first-generation cephalosporin and a frontline clinical anti-infective drug, suitable for the treatment of infections caused by sensitive bacteria such as otitis media, bronchitis, pneumonia, respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, etc.
Are Robust Financials Driving The Recent Rally In Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock?
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed DownNo Data
No Data
